MedStar Washington Hospital Center: Annual Meeting of the Diabetes in Pregnancy Study Group of North America

Meeting ID
4564-13
Series ID
2013

Postpartum care after gestational diabetes is preconception care as well

Article Type
Changed
Tue, 05/03/2022 - 15:51
Display Headline
Postpartum care after gestational diabetes is preconception care as well

WASHINGTON – The rise in gestational diabetes cases demands new strategies for active postpartum care that will not only assist with prevention of type 2 diabetes, but will also prepare women for healthy subsequent pregnancies. New approaches to postpartum care aimed at preventing gestational diabetes in subsequent pregnancies were showcased during sessions at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The problem is a growing one, with the prevalence of gestational diabetes mellitus (GDM) pregnancies ranging from 2% to 10% depending on screening criteria and demographics/population. The prevalence could rise as high as 18% if diagnostic criteria change in the United States to implement the single-step test recommended in 2008 by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and adopted by the American Diabetes Association and the World Health Organization.

Dr. Thomas R. Moore

For now, most U.S. obstetricians are continuing to use the two-step approach to diagnosing GDM, following the advice of a National Institutes of Health consensus development panel and the American College of Gynecologists and Obstetricians. Some physicians, however, are lowering their diagnostic thresholds to capture more at-risk women.

And in the meantime, the prevalence of obesity continues to rise, independently increasing the number of pregnancies complicated by GDM. An estimated 50% of GDM is caused by overweight and obesity, according to Dr. Wanda K. Nicholson, director of the diabetes and obesity core at the University of North Carolina’s Center for Women's Health Research in Chapel Hill.

"We’re not even able to manage our current body of patients," she said. "If we expand this number, we’ll definitely need to develop some new strategies." Studies have also shown that approximately 50% of patients with GDM are screened after delivery for persistent glucose intolerance.

"For most of us, preconception care is increasingly about postpartum care," said Dr. Thomas R. Moore, professor and chairman of the department of reproductive medicine at the University of California, San Diego. "We have to find ways of improving our postpartum follow-up [of GDM pregnancies]."

Follow-up should include checking glycemic status, educating and counseling patients on the risks to newborns of both high maternal HbA1c levels and maternal obesity, assisting patients with nutritional and lifestyle change, advising the use of effective contraception until conditions are right for another pregnancy, and ensuring proper folic acid supplementation before conception is attempted, he said.

For ob.gyn. practices, more GDM can mean more physician appointments, more staff dedicated to coordinating visits with physicians and educators, expanded diabetes education, and expanded nutritional counseling. "In particular, many practices will need to expand their capacity for nutritional counseling," Dr. Nicholson said. "We know from large randomized trials that even for women with mild GDM, nutritional counseling makes a difference."

The literature hints at the possible promise of using telephonic nurse management and Internet-based self-monitoring and educational tools to enhance the postpartum care of new mothers who had GDM, she said.

At the University of North Carolina, a program called the Gestational Diabetes Management System (GooDMomS) offers women video-supported lessons on GDM, a Web and mobile self-monitoring diary in which they can track their weight and record time spent exercising postpartum, as well as forums to "ask the staff" questions and to communicate with other mothers. The system, which is being pilot-tested in an NIH-funded randomized study, is meant to enhance – not replace – basic postpartum care.

In terms of postpartum testing for type 2 diabetes, a recently published literature review suggests that systematic efforts to proactively contact patients can have an impact. Programs in which patients were contacted via phone calls, mailings, and other reminders increased postpartum testing rates from an average of 33% up to 60% (Prim. Care Diabetes 2013;7:177-86).

"We can’t even begin to deliver a preconception program to women until we know what her glycemic status is," emphasized Dr. Moore.

A meta-analysis published more than a decade ago showed an overall 80% reduction in the incidence of congenital malformations in women with diabetes who received preconception care as compared to those who did not receive such care. This study has increasingly relevance today, with more than 76 million women worldwide at risk of their pregnancies being complicated by pregestational (existing) diabetes or gestational diabetes, he said.

The analysis (QJM 2001;94:435-44) also showed that "only modest reductions in HbA1c, averaging 17%, can have a profound impact," Dr. Moore said. The patient conversation must go beyond merely recommending that HbA1c levels be as close to normal as possible before conception is attempted, he emphasized.

 

 

A recent report from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS) shows that women with diabetes were the least likely group among women with various preconception medical problems to report contraception use (Contraception 2013;88:263-8). "They had the lowest uptake on contraception," Dr. Moore said.

An estimate of the "downstream savings" of preventing type 2 diabetes in women with GDM was factored into one of two true cost-effectiveness analyses that have been published thus far of the IADPSG criteria, according to Dr. Aaron B. Caughey, chairman of the department of obstetrics and gynecology at the Oregon Health and Science University in Portland.

Both of the two published analyses concluded that the IADPSG criteria are cost effective, but one of them concluded that the criteria would be cost effective only if post-delivery care reduces diabetes incidence (Diabetes Care 2012;35:529-35).

"The short-term costs (of the one-step approach) are easy to figure out," said Dr. Caughey, an ob.gyn and health economist who also is director of the university’s Center for Women’s Health. "The long-term costs are really tough ... we don’t know, what the impact 20 years downstream is going to be."

Providers at Oregon Health and Science University have been encouraged to adopt the one-step approach and, thus far, the change has resulted in a doubling of GDM incidence from approximately 6% to 12%, he noted.

Dr. Caughey, Dr. Moore, and Dr. Nicholson each reported that they had no conflicts of interest to disclose.

Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
gestational diabetes, postpartum care, type 2 diabetes, pregnancy, gestational diabetes mellitus, GDM,
Sections
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

WASHINGTON – The rise in gestational diabetes cases demands new strategies for active postpartum care that will not only assist with prevention of type 2 diabetes, but will also prepare women for healthy subsequent pregnancies. New approaches to postpartum care aimed at preventing gestational diabetes in subsequent pregnancies were showcased during sessions at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The problem is a growing one, with the prevalence of gestational diabetes mellitus (GDM) pregnancies ranging from 2% to 10% depending on screening criteria and demographics/population. The prevalence could rise as high as 18% if diagnostic criteria change in the United States to implement the single-step test recommended in 2008 by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and adopted by the American Diabetes Association and the World Health Organization.

Dr. Thomas R. Moore

For now, most U.S. obstetricians are continuing to use the two-step approach to diagnosing GDM, following the advice of a National Institutes of Health consensus development panel and the American College of Gynecologists and Obstetricians. Some physicians, however, are lowering their diagnostic thresholds to capture more at-risk women.

And in the meantime, the prevalence of obesity continues to rise, independently increasing the number of pregnancies complicated by GDM. An estimated 50% of GDM is caused by overweight and obesity, according to Dr. Wanda K. Nicholson, director of the diabetes and obesity core at the University of North Carolina’s Center for Women's Health Research in Chapel Hill.

"We’re not even able to manage our current body of patients," she said. "If we expand this number, we’ll definitely need to develop some new strategies." Studies have also shown that approximately 50% of patients with GDM are screened after delivery for persistent glucose intolerance.

"For most of us, preconception care is increasingly about postpartum care," said Dr. Thomas R. Moore, professor and chairman of the department of reproductive medicine at the University of California, San Diego. "We have to find ways of improving our postpartum follow-up [of GDM pregnancies]."

Follow-up should include checking glycemic status, educating and counseling patients on the risks to newborns of both high maternal HbA1c levels and maternal obesity, assisting patients with nutritional and lifestyle change, advising the use of effective contraception until conditions are right for another pregnancy, and ensuring proper folic acid supplementation before conception is attempted, he said.

For ob.gyn. practices, more GDM can mean more physician appointments, more staff dedicated to coordinating visits with physicians and educators, expanded diabetes education, and expanded nutritional counseling. "In particular, many practices will need to expand their capacity for nutritional counseling," Dr. Nicholson said. "We know from large randomized trials that even for women with mild GDM, nutritional counseling makes a difference."

The literature hints at the possible promise of using telephonic nurse management and Internet-based self-monitoring and educational tools to enhance the postpartum care of new mothers who had GDM, she said.

At the University of North Carolina, a program called the Gestational Diabetes Management System (GooDMomS) offers women video-supported lessons on GDM, a Web and mobile self-monitoring diary in which they can track their weight and record time spent exercising postpartum, as well as forums to "ask the staff" questions and to communicate with other mothers. The system, which is being pilot-tested in an NIH-funded randomized study, is meant to enhance – not replace – basic postpartum care.

In terms of postpartum testing for type 2 diabetes, a recently published literature review suggests that systematic efforts to proactively contact patients can have an impact. Programs in which patients were contacted via phone calls, mailings, and other reminders increased postpartum testing rates from an average of 33% up to 60% (Prim. Care Diabetes 2013;7:177-86).

"We can’t even begin to deliver a preconception program to women until we know what her glycemic status is," emphasized Dr. Moore.

A meta-analysis published more than a decade ago showed an overall 80% reduction in the incidence of congenital malformations in women with diabetes who received preconception care as compared to those who did not receive such care. This study has increasingly relevance today, with more than 76 million women worldwide at risk of their pregnancies being complicated by pregestational (existing) diabetes or gestational diabetes, he said.

The analysis (QJM 2001;94:435-44) also showed that "only modest reductions in HbA1c, averaging 17%, can have a profound impact," Dr. Moore said. The patient conversation must go beyond merely recommending that HbA1c levels be as close to normal as possible before conception is attempted, he emphasized.

 

 

A recent report from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS) shows that women with diabetes were the least likely group among women with various preconception medical problems to report contraception use (Contraception 2013;88:263-8). "They had the lowest uptake on contraception," Dr. Moore said.

An estimate of the "downstream savings" of preventing type 2 diabetes in women with GDM was factored into one of two true cost-effectiveness analyses that have been published thus far of the IADPSG criteria, according to Dr. Aaron B. Caughey, chairman of the department of obstetrics and gynecology at the Oregon Health and Science University in Portland.

Both of the two published analyses concluded that the IADPSG criteria are cost effective, but one of them concluded that the criteria would be cost effective only if post-delivery care reduces diabetes incidence (Diabetes Care 2012;35:529-35).

"The short-term costs (of the one-step approach) are easy to figure out," said Dr. Caughey, an ob.gyn and health economist who also is director of the university’s Center for Women’s Health. "The long-term costs are really tough ... we don’t know, what the impact 20 years downstream is going to be."

Providers at Oregon Health and Science University have been encouraged to adopt the one-step approach and, thus far, the change has resulted in a doubling of GDM incidence from approximately 6% to 12%, he noted.

Dr. Caughey, Dr. Moore, and Dr. Nicholson each reported that they had no conflicts of interest to disclose.

WASHINGTON – The rise in gestational diabetes cases demands new strategies for active postpartum care that will not only assist with prevention of type 2 diabetes, but will also prepare women for healthy subsequent pregnancies. New approaches to postpartum care aimed at preventing gestational diabetes in subsequent pregnancies were showcased during sessions at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The problem is a growing one, with the prevalence of gestational diabetes mellitus (GDM) pregnancies ranging from 2% to 10% depending on screening criteria and demographics/population. The prevalence could rise as high as 18% if diagnostic criteria change in the United States to implement the single-step test recommended in 2008 by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and adopted by the American Diabetes Association and the World Health Organization.

Dr. Thomas R. Moore

For now, most U.S. obstetricians are continuing to use the two-step approach to diagnosing GDM, following the advice of a National Institutes of Health consensus development panel and the American College of Gynecologists and Obstetricians. Some physicians, however, are lowering their diagnostic thresholds to capture more at-risk women.

And in the meantime, the prevalence of obesity continues to rise, independently increasing the number of pregnancies complicated by GDM. An estimated 50% of GDM is caused by overweight and obesity, according to Dr. Wanda K. Nicholson, director of the diabetes and obesity core at the University of North Carolina’s Center for Women's Health Research in Chapel Hill.

"We’re not even able to manage our current body of patients," she said. "If we expand this number, we’ll definitely need to develop some new strategies." Studies have also shown that approximately 50% of patients with GDM are screened after delivery for persistent glucose intolerance.

"For most of us, preconception care is increasingly about postpartum care," said Dr. Thomas R. Moore, professor and chairman of the department of reproductive medicine at the University of California, San Diego. "We have to find ways of improving our postpartum follow-up [of GDM pregnancies]."

Follow-up should include checking glycemic status, educating and counseling patients on the risks to newborns of both high maternal HbA1c levels and maternal obesity, assisting patients with nutritional and lifestyle change, advising the use of effective contraception until conditions are right for another pregnancy, and ensuring proper folic acid supplementation before conception is attempted, he said.

For ob.gyn. practices, more GDM can mean more physician appointments, more staff dedicated to coordinating visits with physicians and educators, expanded diabetes education, and expanded nutritional counseling. "In particular, many practices will need to expand their capacity for nutritional counseling," Dr. Nicholson said. "We know from large randomized trials that even for women with mild GDM, nutritional counseling makes a difference."

The literature hints at the possible promise of using telephonic nurse management and Internet-based self-monitoring and educational tools to enhance the postpartum care of new mothers who had GDM, she said.

At the University of North Carolina, a program called the Gestational Diabetes Management System (GooDMomS) offers women video-supported lessons on GDM, a Web and mobile self-monitoring diary in which they can track their weight and record time spent exercising postpartum, as well as forums to "ask the staff" questions and to communicate with other mothers. The system, which is being pilot-tested in an NIH-funded randomized study, is meant to enhance – not replace – basic postpartum care.

In terms of postpartum testing for type 2 diabetes, a recently published literature review suggests that systematic efforts to proactively contact patients can have an impact. Programs in which patients were contacted via phone calls, mailings, and other reminders increased postpartum testing rates from an average of 33% up to 60% (Prim. Care Diabetes 2013;7:177-86).

"We can’t even begin to deliver a preconception program to women until we know what her glycemic status is," emphasized Dr. Moore.

A meta-analysis published more than a decade ago showed an overall 80% reduction in the incidence of congenital malformations in women with diabetes who received preconception care as compared to those who did not receive such care. This study has increasingly relevance today, with more than 76 million women worldwide at risk of their pregnancies being complicated by pregestational (existing) diabetes or gestational diabetes, he said.

The analysis (QJM 2001;94:435-44) also showed that "only modest reductions in HbA1c, averaging 17%, can have a profound impact," Dr. Moore said. The patient conversation must go beyond merely recommending that HbA1c levels be as close to normal as possible before conception is attempted, he emphasized.

 

 

A recent report from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS) shows that women with diabetes were the least likely group among women with various preconception medical problems to report contraception use (Contraception 2013;88:263-8). "They had the lowest uptake on contraception," Dr. Moore said.

An estimate of the "downstream savings" of preventing type 2 diabetes in women with GDM was factored into one of two true cost-effectiveness analyses that have been published thus far of the IADPSG criteria, according to Dr. Aaron B. Caughey, chairman of the department of obstetrics and gynecology at the Oregon Health and Science University in Portland.

Both of the two published analyses concluded that the IADPSG criteria are cost effective, but one of them concluded that the criteria would be cost effective only if post-delivery care reduces diabetes incidence (Diabetes Care 2012;35:529-35).

"The short-term costs (of the one-step approach) are easy to figure out," said Dr. Caughey, an ob.gyn and health economist who also is director of the university’s Center for Women’s Health. "The long-term costs are really tough ... we don’t know, what the impact 20 years downstream is going to be."

Providers at Oregon Health and Science University have been encouraged to adopt the one-step approach and, thus far, the change has resulted in a doubling of GDM incidence from approximately 6% to 12%, he noted.

Dr. Caughey, Dr. Moore, and Dr. Nicholson each reported that they had no conflicts of interest to disclose.

Publications
Publications
Topics
Article Type
Display Headline
Postpartum care after gestational diabetes is preconception care as well
Display Headline
Postpartum care after gestational diabetes is preconception care as well
Legacy Keywords
gestational diabetes, postpartum care, type 2 diabetes, pregnancy, gestational diabetes mellitus, GDM,
Legacy Keywords
gestational diabetes, postpartum care, type 2 diabetes, pregnancy, gestational diabetes mellitus, GDM,
Sections
Article Source

AT THE ANNUAL MEETING OF THE DIABETES IN PREGNANCY STUDY GROUP

PURLs Copyright

Inside the Article

Long-term GDM Risks Remain Susceptible to Intervention

Article Type
Changed
Tue, 05/03/2022 - 15:51
Display Headline
Long-term GDM Risks Remain Susceptible to Intervention

WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


Meeting/Event
Author and Disclosure Information

Christine Kilgore, Family Practice News Digital Network

Publications
Topics
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Author and Disclosure Information

Christine Kilgore, Family Practice News Digital Network

Author and Disclosure Information

Christine Kilgore, Family Practice News Digital Network

Meeting/Event
Meeting/Event

WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


Publications
Publications
Topics
Article Type
Display Headline
Long-term GDM Risks Remain Susceptible to Intervention
Display Headline
Long-term GDM Risks Remain Susceptible to Intervention
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Article Source

FROM THE ANNUAL MEETING OF THE DIABETES IN PREGNANCY STUDY GROUP

PURLs Copyright

Inside the Article

Long-term GDM risks remain susceptible to intervention

Article Type
Changed
Fri, 01/18/2019 - 13:10
Display Headline
Long-term GDM risks remain susceptible to intervention

WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


Click for Credit Link
Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Click for Credit Link
Click for Credit Link
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


WASHINGTON – Women with a history of gestational diabetes have a sustained long-term risk of developing type 2 diabetes, and this risk continues to be modifiable with either metformin or lifestyle intervention, according to a 10-year follow-up of women who participated in the National Institutes of Health–funded Diabetes Prevention Program trial.

"Even years out from their index pregnancy, women with a history of gestational diabetes are at a significantly increased and sustained risk [compared with women without a GDM history] of developing type 2 [diabetes] ... despite similar baseline metabolic status and despite similar clinical evidence of risk," said Dr. Vanita R. Aroda, who has served as a subinvestigator in the Diabetes Prevention Program (DPP).

Post-hoc analyses of follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS) show that while lifestyle intervention was similarly effective in reducing risk for all parous women (regardless of whether they had GDM), metformin was effective only in women with a history of GDM, Dr. Aroda reported at the annual meeting of the Diabetes in Pregnancy Study Group of North America.

The original DPP enrolled more than 3,000 individuals at high risk of developing diabetes. Participants were at least 25 years old, were overweight or obese, and had impaired glucose tolerance with fasting plasma glucose levels of 92-125 mg/dL and glucose levels of 140-199 mg/dL 2 hours after a 75-g oral glucose tolerance test.

Approximately 2,100 of the participants were women, 350 of whom had GDM "about 12 years prior," explained Dr. Aroda of Georgetown University, Washington.

Participants were randomized in the main study to placebo, lifestyle intervention, or metformin for approximately 3 years. In women with a history of GDM, lifestyle intervention and metformin reduced the progression to diabetes over this time by 53% and 50%, compared with placebo.

The effects of metformin were greater in these women than in the population as a whole, for which the risk reduction from metformin was 31%. For women without a history of GDM, the risk reduction from metformin was insignificant. Lifestyle intervention – which involved at least 7% weight loss, 150 minutes of activity per week, and a low-fat diet – was similarly effective for all groups.

The long-term DPPOS began after the DPP concluded, with the majority of the original cohort continuing in the follow-up. All participants in the DPPOS received basic lifestyle education at this point, because of its proven benefits. Those originally randomized to the lifestyle group received additional education/support, while those originally assigned to receive metformin or placebo continued in these study groups.

At a mean of 10 years’ follow-up, women with a history of GDM in the placebo group had a 65% higher risk of developing type 2 diabetes compared with women without a history of GDM – despite the fact these women were approximately 9 years younger than those without the GDM history, and an average of 20 years past their index pregnancy, Dr. Aroda said.

Metformin and lifestyle reduced progression to diabetes similarly among those with a GDM history (41% and 35%), compared with placebo. These intervention effects were greater than in those without a GDM history, who saw a 28% risk reduction from lifestyle and an insignificant reduction with metformin.

"For women with a history of GDM, the effectiveness of the initial interventions – lifestyle and metformin – was sustained. There were very nice risk reductions with both," Dr. Aroda said.

The GDM and non-GDM cohorts of women had a similar baseline body mass index and similar fasting and post–oral glucose tolerance test glucose levels. It is not clear why women without prior GDM had a lesser response to metformin, but "it could be that these women had healthier beta-cell function," she said.

Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.


Publications
Publications
Topics
Article Type
Display Headline
Long-term GDM risks remain susceptible to intervention
Display Headline
Long-term GDM risks remain susceptible to intervention
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Legacy Keywords
Women, gestational diabetes, type 2 diabetes, metformin, lifestyle intervention, National Institutes of Health, Diabetes Prevention Program trial, pregnancy,
Article Source

FROM THE ANNUAL MEETING OF THE DIABETES IN PREGNANCY STUDY GROUP

PURLs Copyright

Inside the Article

Vitals

Major finding: Women with a history of GDM who received no intervention for diabetes prevention had a 65% higher risk of developing diabetes at 10-year follow-up compared with parous women without a history of GDM. Metformin and lifestyle reduced progression to diabetes in women with a GDM history by 41% and 35%, respectively, compared with placebo.

Data source: The Diabetes Prevention Program Outcomes Study, a longitudinal follow-up study of the NIH-funded Diabetes Prevention Program randomized prospective study.

Disclosures: Dr. Aroda reported that she receives consulting fees and grant support from Novo Nordisk and Sanofi-Aventis, as well as grant support from Bristol-Myers Squibb, GlaxoSmithKline, Integrium, Takeda Pharmaceuticals, and Boehringer Ingelheim Vetmedica GmbH.